@phdthesis{Jung2016,
  author    = {Jung, Lisa Anna},
  title     = {Targeting MYC Function as a Strategy for Tumor Therapy},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-146993},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2016},
  abstract  = {A large fraction of human tumors exhibits aberrant expression of the oncoprotein MYC. As a transcription factor regulating various cellular processes, MYC is also crucially involved in normal development. Direct targeting of MYC has been a major challenge for molecular cancer drug discovery. The proof of principle that its inhibition is nevertheless feasible came from in vivo studies using a dominant-negative allele of MYC termed OmoMYC. Systemic expression of OmoMYC triggered long-term tumor regression with mild and fully reversible side effects on normal tissues. In this study, OmoMYC's mode of action was investigated combining methods of structural biology and functional genomics to elucidate how it is able to preferentially affect oncogenic functions of MYC. The crystal structure of the OmoMYC homodimer, both in the free and the E-box-bound state, was determined, which revealed that OmoMYC forms a stable homodimer, and as such, recognizes DNA via the same base-specific DNA contacts as the MYC/MAX heterodimer. OmoMYC binds DNA with an equally high affinity as MYC/MAX complexes. RNA-sequencing showed that OmoMYC blunts both MYC-dependent transcriptional activation and repression. Genome-wide DNA-binding studies using chromatin immunoprecipitation followed by high-throughput sequencing revealed that OmoMYC competes with MYC/MAX complexes on chromatin, thereby reducing their occupancy at consensus DNA binding sites. The most prominent decrease in MYC binding was seen at low-affinity promoters, which were invaded by MYC at oncogenic levels. Strikingly, gene set enrichment analyses using OmoMYC-regulated genes enabled the identification of tumor subgroups with high MYC levels in multiple tumor entities. Together with a targeted shRNA screen, this identified novel targets for the eradication of MYC-driven tumors, such as ATAD3A, BOP1, and ADRM1. In summary, the findings suggest that OmoMYC specifically inhibits tumor cell growth by attenuating the expression of rate-limiting proteins in cellular processes that respond to elevated levels of MYC protein using a DNA-competitive mechanism. This opens up novel strategies to target oncogenic MYC functions for tumor therapy.},
  subject      = {Myc},
  language  = {en}
}
@phdthesis{Carstensen2018,
  author    = {Carstensen, Anne Carola},
  title     = {Identification of novel N-MYC interacting proteins reveals N-MYC interaction with TFIIIC},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-143658},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {N-MYC is a member of the human MYC proto-oncogene family, which comprises three transcription factors (C-, N- and L-MYC) that function in multiple biological processes. Deregulated expression of MYC proteins is linked to tumour initiation, maintenance and progression. For example, a large fraction of neuroblastoma displays high N-MYC levels due to an amplification of the N-MYC encoding gene. MYCN-amplified neuroblastoma depend on high N-MYC protein levels, which are maintained by Aurora-A kinase. Aurora-A interaction with N-MYC interferes with degradation of N-MYC via the E3 ubiquitin ligase SCFFBXW7. However, the underlying mechanism of Aurora-A-mediated stabilisation of N-MYC remains to be elucidated. To identify novel N-MYC interacting proteins, which could be involved in N-MYC stabilisation by Aurora-A, a proteomic analysis of purified N-MYC protein complexes was conducted. Since two alanine mutations in MBI of N-MYC, T58A and S62A (N-MYC mut), disable Aurora-A-mediated stabilisation of N-MYC, N-MYC protein complexes from cells expressing either N-MYC wt or mut were analysed. Proteomic analysis revealed that N-MYC interacts with two deubiquitinating enzymes, USP7 and USP11, which catalyse the removal of ubiquitin chains from target proteins, preventing recognition by the proteasome and subsequent degradation. Although N-MYC interaction with USP7 and USP11 was confirmed in subsequent immunoprecipitation experiments, neither USP7, nor USP11 was shown to be involved in the regulation of N-MYC stability. Besides USP7/11, proteomic analyses identified numerous additional N-MYC interacting proteins that were not described to interact with MYC transcription factors previously. Interestingly, many of the identified N-MYC interaction partners displayed a preference for the interaction with N-MYC wt, suggesting a MBI-dependent interaction. Among these were several proteins, which are involved in three-dimensional organisation of chromatin domains and transcriptional elongation by POL II. Not only the interaction of N-MYC with proteins functioning in elongation, such as the DSIF component SPT5 and the PAF1C components CDC73 and CTR9, was validated in immunoprecipitation experiments, but also with the POL III transcription factor TFIIIC and topoisomerases TOP2A/B. ChIP-sequencing analysis of N-MYC and TFIIIC subunit 5 (TFIIIC5) revealed a large number of joint binding sites in POL II promoters and intergenic regions, which are characterised by the presence of a specific motif that is highly similar to the CTCF motif. Additionally, N-MYC was shown to interact with the ring-shaped cohesin complex that is known to bind to CTCF motifs and to assist the insulator protein CTCF. Importantly, individual ChIP experiments demonstrated that N-MYC, TFIIIC5 and cohesin subunit RAD21 occupy joint binding sites comprising a CTCF motif. Collectively, the results indicate that N-MYC functions in two biological processes that have not been linked to MYC biology previously. Furthermore, the identification of joint binding sites of N-MYC, TFIIIC and cohesin and the confirmation of their interaction with each other suggests a novel function of MYC transcription factors in three-dimensional organisation of chromatin.},
  subject      = {Biologie},
  language  = {en}
}
@phdthesis{Dirks2019,
  author    = {Dirks, Johannes},
  title     = {Charakterisierung der Wechselwirkung zwischen N-Myc und Aurora-A im MYCN-amplifizierten Neuroblastom},
  doi       = {10.25972/OPUS-18660},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-186600},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {Im Neuroblastom ist die Amplifikation des MYCN-Gens, eines Mitglieds der MYC-Onkogenfamilie, mit einer ung{\"u}nstigen Prognose assoziiert. Der von dem Gen kodierte Transkriptionsfaktor N-Myc ist f{\"u}r die Proliferation der MYCN-amplifizierten Neuroblastomzelllinien notwendig und seine Depletion oder Destabilisierung f{\"u}hren zum Proliferationsarrest (Otto et al., 2009). Da N-Myc auf Proteinebene durch die Interaktion mit der mitotischen Kinase Aurora-A stabilisiert wird, bewirkt deren Depletion oder die Hemmung der Interaktion der beiden Proteine mittels spezieller Aurora- A-Inhibitoren (z.B. MLN8054 und MLN8237) ebenso eine Hemmung der Proliferation - in vitro und in vivo (Brockmann et al., 2013). Bisher ist jedoch unklar, {\"u}ber welchen Mechanismus Aurora-A die Stabilisierung von N-Myc erreicht, die Kinaseaktivit{\"a}t spielt hierbei jedoch keine Rolle (Otto et al., 2009). Eine M{\"o}glichkeit stellt die Rekrutierung von Usps dar, die das angeh{\"a}ngte Ubiquitinsignal so modifizieren, dass die Erkennung und der Abbau des Proteins durch das Proteasom verringert werden. In der vorliegenden Arbeit wurde die Wirkung von Usp7 und Usp11 auf die Stabilit{\"a}t von N-Myc untersucht. F{\"u}r beide konnte in Immunpr{\"a}zipitationen die Interaktion mit N-Myc gezeigt werden. Ebenso erh{\"o}hten beide Proteasen in {\"U}berexpressionsexperimenten die vorhandene Menge an NMyc. Die Depletion von Usp7 mittels shRNAs f{\"u}hrte in IMR-32 zu einem Arrest in der G1-Phase und zur Differenzierung der Zellen. Gleichzeitig wurden stark erniedrigte mRNA- und Proteinmengen von N-Myc und Aurora-A nachgewiesen. Es konnte jedoch nicht eindeutig gezeigt werden, ob die beobachteten zellul{\"a}ren Effekte durch eine vermehrte proteasomale Degradation von N-Myc begr{\"u}ndet sind oder ob dabei die ver{\"a}nderte Regulation weiterer Zielproteine von Usp7 eine Rolle spielt. Die Depletion von Usp11 mit shRNAs bewirkte eine Abnahme der N-Myc-Mengen auf posttranslationaler Ebene. Somit stellen beide Usps vielversprechende Angriffspunkte einer gezielten Therapie in MYCN-amplifizierten Neuroblastomen dar und sollten deshalb Gegenstand weiterf{\"u}hrender Untersuchungen sein. {\"U}ber welche Proteindom{\"a}ne in N-Myc die Interaktion mit Aurora-A stattfindet ist nicht bekannt. Eine m{\"o}gliche Pseudosubstratbindungssequenz in Myc-Box I (Idee Richard Bayliss, University of Leicester) wurde in der vorliegenden Arbeit untersucht. Durch Mutation dieser Sequenz sollte die Bindung von Aurora-A unm{\"o}glich gemacht werden. Allerdings wurde die erwartete Abnahme der St{\"a}rke der Interaktion von Aurora-A und N-Myc durch die Mutation ebensowenig beobachtet wie eine verringerte Stabilit{\"a}t. Die Regulation der Phosphorylierung von N-Myc im Verlauf des Zellzyklus wurde durch die Mutation beeintr{\"a}chtigt. Wie diese Ver{\"a}nderung exakt zu begr{\"u}nden ist bedarf weiterer Experimente},
  subject      = {Neuroblastom},
  language  = {de}
}
@phdthesis{Jaenicke2015,
  author    = {J{\"a}nicke, Laura Annika},
  title     = {Regulation of MYC Activity by the Ubiquitin-Proteasome System},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-123339},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {The oncogenic MYC protein is a transcriptional regulator of multiple cellular processes and is aberrantly activated in a wide range of human cancers. MYC is an unstable protein rapidly degraded by the ubiquitin-proteasome system. Ubiquitination can both positively and negatively affect MYC function, but its direct contribution to MYC-mediated transactivation remained unresolved. To investigate how ubiquitination regulates MYC activity, a non-ubiquitinatable MYC mutant was characterized, in which all lysines are replaced by arginines (K-less MYC). The absence of ubiquitin-acceptor sites in K-less MYC resulted in a more stable protein, but did not affect cellular localization, chromatin-association or the ability to interact with known MYC interaction partners. Unlike the wild type protein, K-less MYC was unable to promote proliferation in immortalized mammary epithelial cells. RNA- and ChIP-Sequencing analyses revealed that, although K-less MYC was present at MYC-regulated promoters, it was a weaker transcriptional regulator. The use of K-less MYC, a proteasomal inhibitor and reconstitution of individual lysine residues showed that proteasomal turnover of MYC is required for MYC target gene induction. ChIP-Sequencing of RNA polymerase II (RNAPII) revealed that MYC ubiquitination is dispensable for RNAPII recruitment and transcriptional initiation but is specifically required to promote transcriptional elongation. Turnover of MYC is required to stimulate histone acetylation at MYC-regulated promoters, which depends on a highly conserved region in MYC (MYC box II), thereby enabling the recruitment of BRD4 and P-TEFb and the release of elongating RNAPII from target promoters. Inhibition of MYC turnover enabled the identification of an intermediate in MYC-mediated transactivation, the association of MYC with the PAF complex, a positive elongation factor, suggesting that MYC acts as an assembly factor transferring elongation factors onto RNAPII. The interaction between MYC and the PAF complex occurs via a second highly conserved region in MYC's amino terminus, MYC box I. Collectively, the data of this work show that turnover of MYC coordinates histone acetylation with recruitment and transfer of elongation factors on RNAPII involving the cooperation of MYC box I and MYC box II.},
  subject      = {Myc},
  language  = {en}
}
@phdthesis{Pfann2020,
  author    = {Pfann, Christina},
  title     = {Untersuchungen zu neuen therapeutischen Ans{\"a}tzen zur Beeinflussung der MYC-Expression im kolorektalen Karzinom},
  doi       = {10.25972/OPUS-21668},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-216687},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {Eine ver{\"a}nderte Expression des Transkriptionsfaktors MYC wird als entscheidender Faktor f{\"u}r Tumorentstehung und -progress im kolorektalen Karzinom gesehen. Somit ist die Hemmung dessen Expression und Funktion ein zentraler Ansatz bei der zielgerichteten Tumortherapie. Als geeignete Strategie, sowohl die Halbwertszeit als auch die Translation von MYC zu verringern, erschien eine duale PI3K-/mTOR-Hemmung durch den small molecule-Inhibitor BEZ235. Gegenteilig ist jedoch unter Behandlung mit BEZ235 eine verst{\"a}rkte MYC-Expression in verschiedenen Kolonkarzinom-Zelllinien zu beobachten. Neben verst{\"a}rkter Transkription, konnte eine verst{\"a}rkte IRES-abh{\"a}ngige Translation von MYC nach Hemmung der mTOR-/5´Cap-abh{\"a}ngigen Translation durch BEZ235, als Ursache der MYC-Induktion nachgewiesen werden. Es konnte gezeigt werden, dass die Induktion von MYC nach PI3K-/mTOR-Hemmung durch eine kompensatorische Aktivierung des MAPK-Signalwegs in Folge einer FOXO-abh{\"a}ngigen Induktion von Rezeptortyrosinkinasen, stattfindet. Eine m{\"o}gliche Strategie, diese Feedback-Mechanismen zu umgehen, ist die direkte Hemmung der Translationsinitiation. Hierf{\"u}r wurden Rocaglamid und dessen Derivat Silvestrol als small molecule-Inhibitoren der eIF4A-Helikase verwendet. Im Gegensatz zur PI3K/mTOR-Hemmung, ist durch eIF4A-Inhibition eine Reduktion der MYC-Proteinexpression in verschiedenen Kolonkarzinom-Zelllinien zu erreichen - ohne einhergehende MAPK-Aktivierung. Anhand der Ergebnisse kann postuliert werden, dass Silvestrol das Potential besitzt, sowohl die Cap-/eIF4F-abh{\"a}ngie als auch die somit eIF4A-abh{\"a}ngige IRES-vermittelte Translation von MYC zu hemmen. Weiterhin kann eine proliferationshemmende Wirkung durch Silvestrol auf Kolonkarzinom-Zellen in vitro, via Zellzyklusarrest und Induktion von Apoptose, gezeigt werden. Dies stellt die Voraussetzung f{\"u}r eine potentielle Eignung als tumorhemmender Wirkstoff in der Therapie des kolorektalen Karzinoms dar.},
  language  = {de}
}
@phdthesis{Roeschert2021,
  author    = {R{\"o}schert, Isabelle},
  title     = {Aurora-A prevents transcription-replication conflicts in MYCN-amplified neuroblastoma},
  doi       = {10.25972/OPUS-24303},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-243037},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {Neuroblastoma is the most abundant, solid, extracranial tumor in early childhood and the leading cause of cancer-related childhood deaths worldwide. Patients with high-risk neuroblastoma often show MYCN-amplification and elevated levels of Aurora-A. They have a low overall survival and despite multimodal therapy options a poor therapeutic prognosis. MYCN-amplified neuroblastoma cells depend on Aurora-A functionality. Aurora-A stabilizes MYCN and prevents it from proteasomal degradation by competing with the E3 ligase SCFFBXW7. Interaction between Aurora-A and MYCN can be observed only in S phase of the cell cycle and activation of Aurora-A can be induced by MYCN in vitro. These findings suggest the existence of a profound interconnection between Aurora-A and MYCN in S phase. Nevertheless, the details remain elusive and were investigated in this study. Fractionation experiments show that Aurora-A is recruited to chromatin in S phase in a MYCN-dependent manner. Albeit being unphosphorylated on the activating T288 residue, Aurora-A kinase activity was still present in S phase and several putative, novel targets were identified by phosphoproteomic analysis. Particularly, eight phosphosites dependent on MYCN-activated Aurora-A were identified. Additionally, phosphorylation of serine 10 on histone 3 was verified as a target of this complex in S phase. ChIP-sequencing experiments reveal that Aurora-A regulates transcription elongation as well as histone H3.3 variant incorporation in S phase. 4sU-sequencing as well as immunoblotting demonstrated that Aurora-A activity impacts splicing. PLA measurements between the transcription and replication machinery revealed that Aurora-A prevents the formation of transcription-replication conflicts, which activate of kinase ATR. Aurora-A inhibitors are already used to treat neuroblastoma but display dose-limiting toxicity. To further improve Aurora-A based therapies, we investigated whether low doses of Aurora-A inhibitor combined with ATR inhibitor could increase the efficacy of the treatment albeit reducing toxicity. The study shows that the combination of both drugs leads to a reduction in cell growth as well as an increase in apoptosis in MYCN-amplified neuroblastoma cells, which is not observable in MYCN non-amplified neuroblastoma cells. This new approach was also tested by a collaboration partner in vivo resulting in a decrease in tumor burden, an increase in overall survival and a cure of 25\% of TH-MYCN mice. These findings indicate indeed a therapeutic window for targeting MYCN-amplified neuroblastoma.},
  subject      = {Neuroblastom},
  language  = {en}
}
@phdthesis{Brockmann2015,
  author    = {Brockmann, Markus},
  title     = {Inhibition von Aurora-A als neue Therapiestrategie gegen MYCN-amplifizierte Neuroblastome},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135951},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Im Neuroblastom ist die Amplifikation des MYCN-Gens, das f{\"u}r den Transkriptionsfaktor N-Myc kodiert, der klinisch bedeutendste Faktor f{\"u}r eine schlechte Prognose. Als Mitglied der onkogenen Myc-Familie induziert N-Myc die Expression von Genen, die in vielen biologischen Prozessen wie Metabolismus, Zellzyklusprogression, Zellwachstum und Apoptose eine wichtige Rolle spielen. Die Deregulation der MYCN-Expression f{\"u}hrt zu einem charakteristischen Genexpressionsprofil und einem aggressiven Phenotyp in den Tumorzellen. In normalen neuronalen Vorl{\"a}uferzellen wird N-Myc gew{\"o}hnlich sehr schnell proteasomal abgebaut. W{\"a}hrend der Mitose wird N-Myc an Serin 62 phosphoryliert. Diese Phosphorylierung dient als Erkennungssignal f{\"u}r die Kinase GSK3β, die die Phosphorylierung an Threonin 58 katalysiert. Das Phosphodegron wird von Fbxw7, einer Komponente des E3-Ubiquitinligase-Komplex SCFFbxw7, erkannt. Die anschließende Ubiquitinierung induziert den proteasomalen Abbau des Proteins. Die Reduktion der N-Myc-Proteinlevel erm{\"o}glicht den neuronalen Vorl{\"a}uferzellen den Austritt aus dem Zellzyklus und f{\"u}hrt zu einer terminalen Differenzierung. In einem shRNA Screen konnte AURKA als essentielles Gen f{\"u}r die Proliferation MYCN-amplifizierter Neuroblastomzellen identifiziert werden. Eine Aurora-A-Depletion hatte jedoch keinen Einfluss auf das Wachstum nicht-amplifizierter Zellen. W{\"a}hrend dieser Doktorarbeit konnte gezeigt werden, dass Aurora-A speziell den Fbxw7-vermittelten Abbau verhindert und dadurch N-Myc stabilisiert. F{\"u}r die Stabilisierung ist zwar die Interaktion der beiden Proteine von entscheidender Bedeutung, {\"u}berraschenderweise spielt die Kinaseaktivit{\"a}t von Aurora-A jedoch keine Rolle. Zwei spezifische Aurora-A-Inhibitoren, MLN8054 und MLN8237, sind allerdings in der Lage, nicht nur die Kinaseaktivit{\"a}t zu hemmen, sondern auch die N-Myc-Proteinlevel zu reduzieren. Beide Molek{\"u}le induzieren eine Konformations{\"a}nderung in der Kinasedom{\"a}ne von Aurora-A. Diese ungew{\"o}hnliche strukturelle Ver{\"a}nderung hat zur Folge, dass der N-Myc/Aurora-A-Komplex dissoziiert und N-Myc mit Hilfe von Fbxw7 proteasomal abgebaut werden kann. In MYCN-amplifizierten Zellen f{\"u}hrt diese Reduktion an N-Myc zu einem Zellzyklusarrest in der G1-Phase. Die in vitro Daten konnten in einem transgenen Maus-Modell f{\"u}r das MYCN-amplifizierte Neuroblastom best{\"a}tigt werden. Die Behandlung mit MLN8054 und MLN8237 f{\"u}hrte in den Tumoren ebenfalls zu einer N-Myc-Reduktion. Dar{\"u}ber hinaus konnte ein prozentualer Anstieg an differenzierten Zellen, die vollst{\"a}ndige Tumorregression in der Mehrzahl der Neuroblastome und eine gesteigerte Lebenserwartung beobachtet werden. Insgesamt zeigen die in vitro und in vivo Daten, dass die spezifischen Aurora-A-Inhibitoren ein hohes therapeutisches Potential gegen das MYCN-amplifizierte Neuroblastom besitzen.},
  subject      = {N-Myc},
  language  = {de}
}
@phdthesis{Wiese2015,
  author    = {Wiese, Katrin Evelyn},
  title     = {Sensing supraphysiological levels of MYC : mechanisms of MIZ1-dependent MYC-induced Apoptosis in Mammary Epithelial Cells},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-132532},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Deregulated MYC expression contributes to cellular transformation as well as progression and maintenance of human tumours. Interestingly, in the absence of additional genetic alterations, potentially oncogenic levels of MYC sensitise cells to a variety of apoptotic stimuli. Hence, MYC-induced apoptosis has long been recognised as a major barrier against cancer development. However, it is largely unknown how cells discriminate physiological from supraphysiological levels of MYC in order to execute an appropriate biological response. The experiments described in this thesis demonstrate that induction of apoptosis in mammary epithelial cells depends on the repressive actions of MYC/MIZ1 complexes. Analysis of gene expression profiles and ChIP-sequencing experiments reveals that high levels of MYC are required to invade low-affinity binding sites and repress target genes of the serum response factor SRF. These genes are involved in cytoskeletal dynamics as well as cell adhesion processes and are likely needed to transmit survival signals to the AKT kinase. Restoration of SRF activity rescues MIZ1- dependent gene repression and increases AKT phosphorylation and downstream function. Collectively, these results indicate that association with MIZ1 leads to an expansion of MYC's transcriptional response that allows sensing of oncogenic levels, which points towards a tumour-suppressive role for the MYC/MIZ1 complex in epithelial cells.},
  subject      = {Myc},
  language  = {en}
}
@phdthesis{Peter2014,
  author    = {Peter, Stefanie},
  title     = {Hemmung der Myc-Funktion durch niedermolekulare Inhibitoren der E3-Ubiquitin-Ligase Huwe1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-104449},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2014},
  abstract  = {Die Deregulation des Transkriptionsfaktors Myc ist ein zentraler Mechanismus in der kolorektalen Karzinogenese. Die Myc-Deletion in Tumormodellen hemmt das Wachstum von Kolonkarzinomen, somit stellt die Inaktivierung von Myc einen Ansatzpunkt in der Behandlung von kolorektalen Tumoren dar. Die direkte Inhibition von Myc ist schwierig, da Myc keine katalytische Aktivit{\"a}t besitzt und stattdessen f{\"u}r die Myc-Funktion n{\"o}tige Protein-Protein- oder Protein-DNA-Interaktionen angegriffen werden m{\"u}ssen. Die E3-Ubiquitin-Ligase Huwe1 interagiert sowohl mit Myc als auch mit dem Myc-interagierenden Protein Miz1 und ist im Kolonkarzinom {\"u}berexprimiert. Huwe1 ubiquitiniert Myc und induziert dar{\"u}ber dessen Transaktivierungsfunktion. Die Inaktivierung von Huwe1 ist somit eine vielversprechende M{\"o}glichkeit f{\"u}r die Inhibition der Myc-Funktion und die Therapie des Kolonkarzinoms. In dieser Arbeit wird mittels shRNA-vermittelter Depletion von Huwe1 in Zellkulturexperimenten gezeigt, dass Huwe1 f{\"u}r die Proliferation von Kolonkarzinomzelllinien und f{\"u}r die Transaktivierung von Myc-Zielgenen ben{\"o}tigt wird. Mit zwei von Boehringer Ingelheim identifizierten niedermolekularen Huwe1-Inhibitoren (BI8622 und BI8626) ist es m{\"o}glich, die Huwe1-Funktion spezifisch in Zellen zu blockieren. Die Huwe1-Inhibitoren induzieren einen Proliferationsarrest in kolorektalen Karzinomzelllinien, wohingegen die Substanzen auf embryonale Stammzellen keine Auswirkungen haben. Die Inaktivierung von Huwe1 f{\"u}hrt zu einer Akkumulation von Miz1 an Promotoren Myc-aktivierter Zielgene und dar{\"u}ber zu einer vermehrten Bildung repressiver Myc/Miz1-Komplexe, was mit einer Deacetylierung von Histon H3 und einer transkriptionellen Repression Myc-gebundener Gene assoziiert ist. Miz1 akkumuliert nach Huwe1-Inhibition ebenso an direkten Miz1-Zielgenen, deren Expression bleibt aber unbeeinflusst. Diese Daten weisen darauf hin, dass eine kontinuierliche Degradierung von Miz1 durch Huwe1 zur Transaktivierung von Myc-Zielgenen in Kolonkarzinomzellen n{\"o}tig ist. Damit wurde ein neuer Mechanismus identifiziert, {\"u}ber den Huwe1 die Myc-Transaktivierung reguliert und der eine tumorzellspezifische Repression der Myc-Funktion mit Hilfe von Huwe1-Inhibitoren erm{\"o}glicht.},
  subject      = {Myc},
  language  = {de}
}
@phdthesis{Xu2014,
  author    = {Xu, Jiajia},
  title     = {A high-complexity lentiviral shRNA screen identifies synthetic lethal interactions with deregulated N-Myc in neuroblastoma cells},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-103157},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2014},
  abstract  = {In contrast to c-Myc, a deregulated expression of the MYCN gene is restricted to human neuroendocrine tumours. In most cases, the excessive activity of N-Myc results from a MYCN amplification. In neuroblastoma, amplification of MYCN is a predictor of poor prognosis and resistance to therapy. The inability to target the N-Myc protein directly necessitates the search for alternative targets. This project aimed at identifying genes specifically required for growth and survival of cells that express high levels of N-Myc using high-throughput shRNA screening combined with next generation sequencing. The identification and analysis of these genes will shed light on functional interaction partners of N-Myc. We screened a shRNA library containing 18,327 shRNAs and identified 148 shRNAs, which were selectively depleted in the presence of active N-Myc. In addition, shRNAs targeting genes that are involved in p53 and ARF turnover and apoptosis were depleted in the cell population during the screen. These processes are known to affect N-Myc-mediated apoptosis. Consequently, these results biologically validated the screen. The 148 shRNAs that showed a significant synthetic lethal interaction with high levels of N-Myc expression were further analysed using the bioinformatics program DAVID. We found an enrichment of shRNAs that target genes involved in specific biological processes. For example, we validated synthetic lethal interactions for genes such as, THOC1, NUP153 and LARP7, which play an important role in the process of RNA polymerase II-mediated transcription elongation. We also validated genes that are involved in the neddylation pathway. In the screen we identified Cullin 3, which is a component of the BTB-CUL3-Rbx1 ubiquitin ligase that is involved in the turnover of Cyclin E. Depletion of cullin 3 and activation of N-Myc was found to synergistically increase Cyclin E expression to supraphysiological levels, inducing S-phase arrest and a strong DNA damage response. Together with results from a proteomics analysis of N-Myc associated proteins, our results lead us to the following hypothesis: In a neuroblastoma cell, the high levels of N-Myc result in a conflict between RNA polymerase II and the replication machinery during S-phase. The newly identified interaction partners of N- Myc are required to solve this conflict. Consequently, loss of the interaction leads to a massive DNA damage and the induction of apoptosis. In addition, inhibition or depletion of the essential components of the neddylation pathway also results in an unresolvable problem during S-phase.},
  subject      = {Neuroblastom},
  language  = {en}
}